As mentioned above, cannabis and hemp differ in the levels of naturally occurring THC that they contain. THC is a cannabinoid like CBD. However, its properties are very different and often antagonistic to the effects of CBD. Hemp is naturally high in CBD and low in THC; the reverse is true of cannabis. In fact, hemp contains only about 0.3% – 1.5% THC, while cannabis contains about 5% – 10% or more THC.
A 2017 article published by the National Academies of Sciences, Engineering and Medicine conducted a study in which the results concluded, “In adults with chronic pain, patients who were treated with cannabis or cannabinoids are more likely to experience a clinically significant reduction in pain symptoms.” This statement is quite a massive development for the increasing of tolerance towards CBD and CBD based products.
Cannabidiol has been found to act as an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It has also been found to act as an inverse agonist of GPR3, GPR6, and GPR12. Although currently classified as orphan receptors, these receptors are most closely related phylogenetically to the cannabinoid receptors. In addition to orphan receptors, CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist, and this action may be involved in its antidepressant, anxiolytic, and neuroprotective effects. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD have additionally been attributed to PPARγ agonism and intracellular calcium release.
In fact, the majority of them report that CBD actually seems to work phenomenally well with the caffeine – they claim that it reduces cases of the “jitters” (which makes sense considering that CBD is a well-known anti-spasmodic), and also that it works wonders in terms of elevating mood, increasing mental acuity, and promoting general productivity.
Naturally, scientists wanted to see if CBD had any anticancer properties. As a result, they performed several animal studies using it. However, it should be noted that the findings don’t fully apply to humans. In fact, they merely suggest what possible effects CBD might have when it comes to dealing with cancer. With that in mind, additional human studies would help conclude if CBD has an effect on cancer cells in humans.
I’ve been hoarding Girl Scouts Thin Mints lately (they’re especially good if you freeze them)—the chocolate is fine, but the peppermint oil is what makes them addicting enough to go through a whole sleeve without getting sick of them. I’m also trying to cut down on sugar, though, and while it would be a huge stretch to say that this peppermint oil-infused clear lip balm is a direct replacement for Girl Scout cookies, it really does have a very satisfying full-mouth taste of peppermint. The CBD oil, which soothes and facilitates healing at the same time, makes this formula an ideal balm for outdoor enthusiasts and or just those who are prone to painfully chapped lips. For those of us with long-hair-don’t-care, it’s not sticky—as a matter of fact, the formula is on the stiff side and won’t cause your hair to stick to your face, a welcome departure from many balms.
Researchers like Blessing are legitimately excited about CBD. It shows real promise in treating previously intractable disorders like schizophrenia, and without the destructive side effects of existing drugs. Still, that doesn’t mean CBD is harmless. Research on drug interactions with CBD is in its infancy, but what is known within the medical community is that CBD can cause serious problems for people taking certain classes of drugs, namely SSRIs (a group of antidepressants including Zoloft and Prozac) and opioids.
Thapa, D., Toguri, J. T., Szczesniak, A. M., & Kelly, A. E. M. (2017, April 1). The non-psychoactive phytocannabinoid, cannabidiol (CBD), and the synthetic derivatives, HU308 and CBD-DMH, reduces hyperalgesia and inflammation in a mouse model of corneal injury [Abstract]. FASEB Journal. Retrieved from https://www.fasebj.org/doi/abs/10.1096/fasebj.31.1_supplement.811.7
FAAH breaks down and removes natural endocannabinoids. CBD stops this breakdown and in turn increases the natural endocannabinoids available to the body. Because endo- cannabinoids have a balancing and healing effect on the body’s numerous systems and functions, CBD’s ability to increase the amount of endocannabinoids available to the body may create a bevy of therapeutic benefits5
Not only are we all made differently, we each have our own unique history with the use of substances, medications, supplements, and other things we put in our body. Because of this, we all have different body chemistry, and this will affect how our body reacts to CBD. As R.R Noall over at Herb puts it, “what works for your friend, may not work for you.”
Medical reviews published in 2017 and 2018 incorporating numerous clinical trials concluded that cannabidiol is an effective treatment for certain types of childhood epilepsy. An orally administered cannabidiol solution (brand name Epidiolex) was approved by the US Food and Drug Administration in June 2018 as a treatment for two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
Every field of interest comes with its own terminology. In the world of CBD, it can seem like there are many terms that are being thrown out there, such as CBD oil, hemp oil, THC oil, cannabis oil, and marijuana oil. With the vast amount of information being introduced, it is easy to confuse one term from the next. We have received numerous questions in regards to the difference between all of these terms.
Despite this, CBD is something nobody knows much about, and certainly nobody is monitoring it properly. CBD is widely marketed as a supplement, despite the Food and Drug Administration saying it does not qualify as such (this is because it is an active ingredient in drugs which are either approved or under investigation to be approved). CBD goes largely unregulated by the agency; on the FDA’s FAQ page, a vague answer maintains there are “many factors in deciding whether or not to initiate an enforcement action.” The Department of Agriculture handles research grants and pilot programs for hemp, but that’s where its involvement ends.